The shortened infusion time of intravenous ibuprofen part 1

A multicenter, open-label, surveillance trial to evaluate safety and efficacy

Sergio D. Bergese, Keith A Candiotti, Sabry S. Ayad, Suren Soghomonyan, Tong J. Gan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose The main purpose of the study was to determine the safety profile and efficacy of intravenous ibuprofen administered over 5 to 10 minutes for the treatment of pain or fever in hospitalized patients. Current evidence supports the use of intravenous infusions of ibuprofen to control pain and reduce the opioid requirements associated with surgical pain. Current dosing guidelines recommend that the drug be administered over 30 minutes. However, a more rapid infusion might yield additional benefits. The safety profile and efficacy of a shortened infusion time requires additional study. Methods This was a Phase IV multicenter, open-label, surveillance clinical study. Thirteen clinical centers located in the United States enrolled a total of 150 adult hospitalized patients with pain or fever. Patients experiencing pain received 800 mg intravenous ibuprofen infused over 5 to 10 minutes every 6 hours for up to 24 hours (4 doses) and patients experiencing fever received 400 mg intravenous ibuprofen infused over 5 to 10 minutes every 4 hours for up to 24 hours (6 doses). Vital signs, adverse events, and pain scores were assessed. The exclusion criteria included inadequate intravenous access; patients younger than 18 years of age; history of allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin, or other nonsteroid anti-inflammatory drugs; active hemorrhage or clinically significant bleeding; pregnancy or nursing; and patients in the perioperative period in the setting of coronary artery bypass graft surgery. Findings Adverse events were reported for 43 of 150 patients (29%). The most common adverse events experienced by patients were infusion site pain in 22 of 150 patients (15%) and flatulence (8 of 150 [5%]). Four patients (3%) discontinued the study drug due to infusion-site pain. In the patients experiencing fever, temperature decreased from baseline over 4 hours (mean [SD] reduction of 1.5 [1.25]°F). In patients experiencing pain, patient-reported visual analog scale scores decreased from baseline over 4 hours (mean [SD] reduction of 27.1 [31.29] mm). Implications The study demonstrates that more rapid administration of intravenous ibuprofen is well tolerated and supports intravenous ibuprofen as an effective treatment for pain and fever in hospitalized patients.

Original languageEnglish
Pages (from-to)360-367
Number of pages8
JournalClinical Therapeutics
Volume37
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Ibuprofen
Intravenous Infusions
Safety
Pain
Fever
Hypersensitivity
Pharmaceutical Preparations
Hemorrhage
Flatulence
Perioperative Period
Vital Signs
Visual Analog Scale
Coronary Artery Bypass
Intravenous Administration
Opioid Analgesics
Aspirin
Nursing
Anti-Inflammatory Agents

Keywords

  • fever
  • ibuprofen
  • intravenous analgesics
  • nonopioid analgesics
  • nonsterioidal antiinflammatory drugs
  • pain

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The shortened infusion time of intravenous ibuprofen part 1 : A multicenter, open-label, surveillance trial to evaluate safety and efficacy. / Bergese, Sergio D.; Candiotti, Keith A; Ayad, Sabry S.; Soghomonyan, Suren; Gan, Tong J.

In: Clinical Therapeutics, Vol. 37, No. 2, 01.02.2015, p. 360-367.

Research output: Contribution to journalArticle

@article{034cbaf31603492bbbcf6db4ae151ee0,
title = "The shortened infusion time of intravenous ibuprofen part 1: A multicenter, open-label, surveillance trial to evaluate safety and efficacy",
abstract = "Purpose The main purpose of the study was to determine the safety profile and efficacy of intravenous ibuprofen administered over 5 to 10 minutes for the treatment of pain or fever in hospitalized patients. Current evidence supports the use of intravenous infusions of ibuprofen to control pain and reduce the opioid requirements associated with surgical pain. Current dosing guidelines recommend that the drug be administered over 30 minutes. However, a more rapid infusion might yield additional benefits. The safety profile and efficacy of a shortened infusion time requires additional study. Methods This was a Phase IV multicenter, open-label, surveillance clinical study. Thirteen clinical centers located in the United States enrolled a total of 150 adult hospitalized patients with pain or fever. Patients experiencing pain received 800 mg intravenous ibuprofen infused over 5 to 10 minutes every 6 hours for up to 24 hours (4 doses) and patients experiencing fever received 400 mg intravenous ibuprofen infused over 5 to 10 minutes every 4 hours for up to 24 hours (6 doses). Vital signs, adverse events, and pain scores were assessed. The exclusion criteria included inadequate intravenous access; patients younger than 18 years of age; history of allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin, or other nonsteroid anti-inflammatory drugs; active hemorrhage or clinically significant bleeding; pregnancy or nursing; and patients in the perioperative period in the setting of coronary artery bypass graft surgery. Findings Adverse events were reported for 43 of 150 patients (29{\%}). The most common adverse events experienced by patients were infusion site pain in 22 of 150 patients (15{\%}) and flatulence (8 of 150 [5{\%}]). Four patients (3{\%}) discontinued the study drug due to infusion-site pain. In the patients experiencing fever, temperature decreased from baseline over 4 hours (mean [SD] reduction of 1.5 [1.25]°F). In patients experiencing pain, patient-reported visual analog scale scores decreased from baseline over 4 hours (mean [SD] reduction of 27.1 [31.29] mm). Implications The study demonstrates that more rapid administration of intravenous ibuprofen is well tolerated and supports intravenous ibuprofen as an effective treatment for pain and fever in hospitalized patients.",
keywords = "fever, ibuprofen, intravenous analgesics, nonopioid analgesics, nonsterioidal antiinflammatory drugs, pain",
author = "Bergese, {Sergio D.} and Candiotti, {Keith A} and Ayad, {Sabry S.} and Suren Soghomonyan and Gan, {Tong J.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.clinthera.2014.12.004",
language = "English",
volume = "37",
pages = "360--367",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "2",

}

TY - JOUR

T1 - The shortened infusion time of intravenous ibuprofen part 1

T2 - A multicenter, open-label, surveillance trial to evaluate safety and efficacy

AU - Bergese, Sergio D.

AU - Candiotti, Keith A

AU - Ayad, Sabry S.

AU - Soghomonyan, Suren

AU - Gan, Tong J.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Purpose The main purpose of the study was to determine the safety profile and efficacy of intravenous ibuprofen administered over 5 to 10 minutes for the treatment of pain or fever in hospitalized patients. Current evidence supports the use of intravenous infusions of ibuprofen to control pain and reduce the opioid requirements associated with surgical pain. Current dosing guidelines recommend that the drug be administered over 30 minutes. However, a more rapid infusion might yield additional benefits. The safety profile and efficacy of a shortened infusion time requires additional study. Methods This was a Phase IV multicenter, open-label, surveillance clinical study. Thirteen clinical centers located in the United States enrolled a total of 150 adult hospitalized patients with pain or fever. Patients experiencing pain received 800 mg intravenous ibuprofen infused over 5 to 10 minutes every 6 hours for up to 24 hours (4 doses) and patients experiencing fever received 400 mg intravenous ibuprofen infused over 5 to 10 minutes every 4 hours for up to 24 hours (6 doses). Vital signs, adverse events, and pain scores were assessed. The exclusion criteria included inadequate intravenous access; patients younger than 18 years of age; history of allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin, or other nonsteroid anti-inflammatory drugs; active hemorrhage or clinically significant bleeding; pregnancy or nursing; and patients in the perioperative period in the setting of coronary artery bypass graft surgery. Findings Adverse events were reported for 43 of 150 patients (29%). The most common adverse events experienced by patients were infusion site pain in 22 of 150 patients (15%) and flatulence (8 of 150 [5%]). Four patients (3%) discontinued the study drug due to infusion-site pain. In the patients experiencing fever, temperature decreased from baseline over 4 hours (mean [SD] reduction of 1.5 [1.25]°F). In patients experiencing pain, patient-reported visual analog scale scores decreased from baseline over 4 hours (mean [SD] reduction of 27.1 [31.29] mm). Implications The study demonstrates that more rapid administration of intravenous ibuprofen is well tolerated and supports intravenous ibuprofen as an effective treatment for pain and fever in hospitalized patients.

AB - Purpose The main purpose of the study was to determine the safety profile and efficacy of intravenous ibuprofen administered over 5 to 10 minutes for the treatment of pain or fever in hospitalized patients. Current evidence supports the use of intravenous infusions of ibuprofen to control pain and reduce the opioid requirements associated with surgical pain. Current dosing guidelines recommend that the drug be administered over 30 minutes. However, a more rapid infusion might yield additional benefits. The safety profile and efficacy of a shortened infusion time requires additional study. Methods This was a Phase IV multicenter, open-label, surveillance clinical study. Thirteen clinical centers located in the United States enrolled a total of 150 adult hospitalized patients with pain or fever. Patients experiencing pain received 800 mg intravenous ibuprofen infused over 5 to 10 minutes every 6 hours for up to 24 hours (4 doses) and patients experiencing fever received 400 mg intravenous ibuprofen infused over 5 to 10 minutes every 4 hours for up to 24 hours (6 doses). Vital signs, adverse events, and pain scores were assessed. The exclusion criteria included inadequate intravenous access; patients younger than 18 years of age; history of allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin, or other nonsteroid anti-inflammatory drugs; active hemorrhage or clinically significant bleeding; pregnancy or nursing; and patients in the perioperative period in the setting of coronary artery bypass graft surgery. Findings Adverse events were reported for 43 of 150 patients (29%). The most common adverse events experienced by patients were infusion site pain in 22 of 150 patients (15%) and flatulence (8 of 150 [5%]). Four patients (3%) discontinued the study drug due to infusion-site pain. In the patients experiencing fever, temperature decreased from baseline over 4 hours (mean [SD] reduction of 1.5 [1.25]°F). In patients experiencing pain, patient-reported visual analog scale scores decreased from baseline over 4 hours (mean [SD] reduction of 27.1 [31.29] mm). Implications The study demonstrates that more rapid administration of intravenous ibuprofen is well tolerated and supports intravenous ibuprofen as an effective treatment for pain and fever in hospitalized patients.

KW - fever

KW - ibuprofen

KW - intravenous analgesics

KW - nonopioid analgesics

KW - nonsterioidal antiinflammatory drugs

KW - pain

UR - http://www.scopus.com/inward/record.url?scp=84923644621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923644621&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2014.12.004

DO - 10.1016/j.clinthera.2014.12.004

M3 - Article

VL - 37

SP - 360

EP - 367

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 2

ER -